Overview

A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis

Status:
Recruiting
Trial end date:
2026-08-01
Target enrollment:
Participant gender:
Summary
A Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy for Subjects With Refractory Lupus Nephritis
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Kyverna Therapeutics
Treatments:
Cyclophosphamide
Fludarabine